Ventfort (VVH Tripeptide): Khavinson Cardiovascular Bioregulator Research Profile 2026
Introduction
Ventfort is a synthetic cardiovascular tissue bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Part of the Khavinson bioregulator family, Ventfort represents a tissue-specific peptide approach to vascular aging and cardiovascular function—a framework generating significant interest in longevity and gerontology research communities.
What Is Ventfort?
Chemical Identity and Composition: Ventfort is a tripeptide synthesized from amino acid sequence Lysine-Glutamic Acid-Aspartic Acid (Lys-Glu-Asp, or K-E-D). Some sources reference Val-Val-His (VVH), though Lys-Glu-Asp (KED) is more frequently cited in Khavinson's published research.
Molecular weight: Approximately 347-378 Daltons. Research-grade purity: HPLC ≥95%, molecular identity via LC-MS, endotoxin <0.25 EU/mg.
Developmental Context: Vladimir Khavinson pioneered the "tissue bioregulator" model—positing that short peptides extracted from or synthesized to mimic organ-specific peptides serve as "gene switches" regulating age-related decline in specific tissues.
Core hypothesis: Each organ contains endogenous peptides that regulate tissue-specific gene expression. During aging, peptide levels decline, contributing to tissue senescence. Exogenous supplementation with organ-derived peptides can restore age-related gene expression patterns. This is tissue-specific and non-toxic due to peptide receptor selectivity.
Supporting work: 400+ published papers on bioregulatory peptides (1980-2026). Research spanning immune, vascular, cartilage, liver, pineal, thyroid, and other tissues. Animal and cell culture evidence showing peptide-specific effects.
Proposed Mechanism of Action
Ventfort targets endothelial cells and vascular smooth muscle through multiple proposed mechanisms:
1. Endothelial Gene Activation: Activates transcription factors in endothelial cells, stimulates collagen I/III synthesis (arterial wall matrix), promotes elastin production (vascular elasticity), enhances nitric oxide synthase (eNOS) expression (vasodilation, endothelial function).
2. Oxidative Stress Reduction: Reduces lipid peroxidation in vascular membranes, lowers superoxide and ROS in endothelial cells, upregulates antioxidant enzymes (SOD, catalase, GPx).
3. Smooth Muscle Function: Normalizes calcium handling in vascular smooth muscle, supports vasomotor reactivity (constrict/relax appropriately), reduces calcification and stiffening.
4. Inflammatory Modulation: Reduces pro-inflammatory cytokines (IL-6, TNF-α), lowers endothelial adhesion molecule expression (VCAM-1, ICAM-1), attenuates atherosclerotic progression.
Tissue-specific targeting: The Lys-Glu-Asp sequence is proposed to be recognized by vascular endothelial cell surface receptors, conferring tissue selectivity. This selectivity minimizes off-target effects and systemic toxicity.
Evidence limitations: Western-published mechanistic validation is limited; most evidence from Khavinson's laboratory using cell culture and animal models.
Research Evidence and Published Studies
Research on Ventfort is predominantly published in Russian-language journals and St. Petersburg Institute publications, with limited peer-review publication in high-impact Western journals.
Key research themes: Animal studies (rat/mouse models of aging, hypertension, ischemia-reperfusion injury, endothelial dysfunction), cell culture studies (human endothelial/smooth muscle cells, gene expression profiling), clinical case series (small observational studies in hypertension/atherosclerosis, outcomes: blood pressure, endothelial function markers, 10-50 participants).
Evidence quality: Strengths include consistent mechanistic hypothesis, reproducible cell culture gene expression, improved vascular function in animal models, long research lineage (40+ years). Limitations: Scarce Western mechanistic validation, no large RCTs, publication bias, limited independent replication, primarily Russian journals.
Epistemic position: Ventfort sits in same evidence category as entire Khavinson family—interesting and primary research group supported, but lacking extensive independent Western validation.
Dosage Protocols and Administration
Lyophilized powder reconstitution: 1-3 mg per vial, sterile water or 0.9% saline, refrigerate (2-8°C) after reconstitution, use within 24 hours.
Subcutaneous injection (most common): Dose 1-3 mg daily or every other day, route subcutaneous (abdominal/deltoid), frequency daily or alternating, duration 10-30 day cycles with 2-4 week breaks.
Oral supplementation (capsule form, lower bioavailability): Dose 100-300 mg daily, lower than parenteral, take once/twice daily with food.
Cycle recommendations: Loading phase 10-14 days daily 1-3 mg, maintenance 10-14 days every-other-day, rest period 2-4 weeks, repeat cycles annually/bi-annually.
Note: These protocols are from published Khavinson clinic literature; individual protocols should be independently designed.
Comparison with Other Cardiovascular Peptides
Cortagen: Cardiac tissue bioregulator targeting cardiac myocytes (heart tissue-specific). Similar gene-regulatory hypothesis, clinical focus on heart function and aging.
Ventfort targets vascular endothelium/smooth muscle. Combined use: Some protocols combine tissue-specific peptides (Ventfort + Cortagen) for comprehensive cardiovascular support.
BPC-157: Broader tissue repair properties, more Western-published mechanistic studies, different mechanism (growth factor/eNGF signaling, not gene-switch hypothesis), use case: acute injury recovery vs. Ventfort for chronic aging.
AOD-9604: Growth hormone secretagogue activity, systemic metabolic effects, different mechanism from Ventfort's tissue-specific approach.
Safety Profile and Available Data
Animal studies (Khavinson lab): No acute toxicity at doses up to 100 mg/kg in rodents, no chronic toxicity at research doses, no mutagenic/teratogenic signals, no organ-specific toxicity.
Clinical case reports (limited): Rare injection site reactions (local erythema, mild swelling), occasional headache or flu-like symptoms (possibly unrelated), no serious adverse events reported.
Important caveats: Safety data primarily from Khavinson's laboratory, limited independent toxicity verification, no long-term safety in healthy populations, unknown medication interactions, pregnancy/nursing contraindicated until evidence available.
Research considerations: For research use only, not approved for human consumption. Users assume all risk. Medical oversight recommended for clinical protocols.
Storage and Reconstitution
Unopened vials: Store at 2-8°C (refrigerated) or room temperature (15-25°C) if specified, shelf life 12-24 months, light-protected vials with desiccant.
Reconstitution protocol: Remove vial, allow to warm, inspect powder (white to off-white), add sterile water/saline per instructions (typically 1-2 mL), swirl gently (avoid foam), wait 2-5 minutes, use within 24 hours.
Quality checks: Verify CoA matches batch, clear solution after reconstitution, no particles, odorless (discard if unusual smell), assume non-sterile unless pharmaceutical-grade.
Sourcing and Availability
Available through: St. Petersburg Institute (direct, pharmaceutical-grade, high cost, limited English support), Russian distributors (intermediate pricing, variable quality), Western research suppliers (increasing availability, competitive pricing, third-party testing, "For Research Use Only").
Supplier evaluation: Verify third-party CoA (HPLC ≥95%), confirm molecular identity (LC-MS), ensure "For Research Use Only" designation, check reviews (Reddit r/peptides, PeptideMind), request batch CoA before purchase, verify supplier longevity (3-5+ years).
Expected pricing (2026): Research-grade $25-60 per 1-3 mg vial, bulk discounts 10-20% for 5+ vials, shipping $10-50 (US domestic $15-25, international $30-60+).
Internal Research and Self-Directed Study
Suggested framework: Literature review (Google Scholar, PubMed), cell culture studies (HUVEC, replicate published effects), biomarker tracking (arterial stiffness, endothelial function, blood pressure), collaboration with academic institutions, detailed documentation.
Limitations: Peptide synthesis/verification requires specialized equipment, clinical endpoint measurement requires specific devices, statistical analysis requires adequate sample sizes, ethical review recommended for human research.
Related Khavinson Bioregulators
Cortagen: Cardiac myocyte peptide. Testagen: Testicular tissue peptide. Epithalon: Pineal tissue peptide. Glandokort: Adrenal tissue peptide. Bronchogen: Lung tissue peptide.
Cross-read profiles for broader understanding of bioregulator framework.
Conclusion
Ventfort represents tissue-specific peptide approach to cardiovascular aging and vascular dysfunction within Khavinson's bioregulator framework. While theoretical mechanism is compelling and primary research group data encouraging, independent Western validation remains limited.
Key takeaways: Interesting mechanistic hypothesis backed by decades of research lineage, reproducible vascular effects in cell culture/animals, limited human clinical trial data, primarily Russian-language publications with scarce Western replication, not approved for human use.
For serious researchers: Merits exploration within rigorous scientific frameworks, preferably in collaboration with academic institutions or structured research programs.
Important Research Disclaimer
For Research Purposes Only: Ventfort not approved for human consumption. This profile is educational and informational in support of scientific research. Does not constitute medical, regulatory, or personal advice. All peptide research should be under rigorous ethical and scientific protocols, preferably with institutional oversight.
Users assume complete responsibility for legal compliance, research material quality/sourcing, and conduct/safety of research undertaken. Consult qualified professionals before undertaking any peptide research.